1864 related articles for article (PubMed ID: 20404251)
1. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC
J Clin Oncol; 2010 Jun; 28(16):2784-95. PubMed ID: 20404251
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC
Arch Pathol Lab Med; 2010 Jun; 134(6):907-22. PubMed ID: 20524868
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
Hammond ME; Hayes DF; Dowsett M; Allred DC; Hagerty KL; Badve S; Fitzgibbons PL; Francis G; Goldstein NS; Hayes M; Hicks DG; Lester S; Love R; Mangu PB; McShane L; Miller K; Osborne CK; Paik S; Perlmutter J; Rhodes A; Sasano H; Schwartz JN; Sweep FC; Taube S; Torlakovic EE; Valenstein P; Viale G; Visscher D; Wheeler T; Williams RB; Wittliff JL; Wolff AC; ;
Arch Pathol Lab Med; 2010 Jul; 134(7):e48-72. PubMed ID: 20586616
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
Allison KH; Hammond MEH; Dowsett M; McKernin SE; Carey LA; Fitzgibbons PL; Hayes DF; Lakhani SR; Chavez-MacGregor M; Perlmutter J; Perou CM; Regan MM; Rimm DL; Symmans WF; Torlakovic EE; Varella L; Viale G; Weisberg TF; McShane LM; Wolff AC
Arch Pathol Lab Med; 2020 May; 144(5):545-563. PubMed ID: 31928354
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Allison KH; Hammond MEH; Dowsett M; McKernin SE; Carey LA; Fitzgibbons PL; Hayes DF; Lakhani SR; Chavez-MacGregor M; Perlmutter J; Perou CM; Regan MM; Rimm DL; Symmans WF; Torlakovic EE; Varella L; Viale G; Weisberg TF; McShane LM; Wolff AC
J Clin Oncol; 2020 Apr; 38(12):1346-1366. PubMed ID: 31928404
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF; ;
J Clin Oncol; 2007 Jan; 25(1):118-45. PubMed ID: 17159189
[TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF;
Arch Pathol Lab Med; 2007; 131(1):18-43. PubMed ID: 19548375
[TBL] [Abstract][Full Text] [Related]
8. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
Allred DC; Carlson RW; Berry DA; Burstein HJ; Edge SB; Goldstein LJ; Gown A; Hammond ME; Iglehart JD; Moench S; Pierce LJ; Ravdin P; Schnitt SJ; Wolff AC
J Natl Compr Canc Netw; 2009 Sep; 7 Suppl 6():S1-S21; quiz S22-3. PubMed ID: 19755043
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
J Clin Oncol; 2013 Nov; 31(31):3997-4013. PubMed ID: 24101045
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
Arch Pathol Lab Med; 2014 Feb; 138(2):241-56. PubMed ID: 24099077
[TBL] [Abstract][Full Text] [Related]
11. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
Asogan AB; Hong GS; Arni Prabhakaran SK
Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
[TBL] [Abstract][Full Text] [Related]
12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
14. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Wolff AC; Hammond MEH; Allison KH; Harvey BE; Mangu PB; Bartlett JMS; Bilous M; Ellis IO; Fitzgibbons P; Hanna W; Jenkins RB; Press MF; Spears PA; Vance GH; Viale G; McShane LM; Dowsett M
Arch Pathol Lab Med; 2018 Nov; 142(11):1364-1382. PubMed ID: 29846104
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
17. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
18. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Estrogen and Progesterone Receptor Antibody Reagents Using Proficiency Testing Data.
Troxell ML; Long T; Hornick JL; Ambaye AB; Jensen KC
Arch Pathol Lab Med; 2017 Oct; 141(10):1402-1412. PubMed ID: 28714765
[TBL] [Abstract][Full Text] [Related]
20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
